Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03762850 Active, not recruiting - Clinical trials for Immunoglobulin A Nephropathy

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

PROTECT
Start date: December 11, 2018
Phase: Phase 3
Study type: Interventional

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

NCT ID: NCT03453619 Active, not recruiting - Lupus Nephritis Clinical Trials

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies

NCT ID: NCT03418779 Active, not recruiting - Clinical trials for IgA Nephropathy at High Risk of Developing ESRD

Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD

TCMWINE
Start date: July 4, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of severe treatment-related adverse events of Yi-Qi-Qing-Jie formula (YQF) combined therapy compared with immunosuppression monotherapy in high-risk IgAN.

NCT ID: NCT03218852 Active, not recruiting - IgA Nephropathy Clinical Trials

Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

e-TOPplus
Start date: December 2016
Phase: Phase 4
Study type: Interventional

This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.

NCT ID: NCT03188887 Active, not recruiting - IgA Nephropathy Clinical Trials

Treatment of IgA Nephropathy According to Renal Lesions

TIGER
Start date: February 20, 2018
Phase: Phase 3
Study type: Interventional

TIGER study (Treatment of IgA nEphropathy according to Renal lesions) is a prospective openly randomized controlled study. The main objective is to evaluate the efficacy of early corticotherapy + Renin Angiotensin System (RAS) blockade or inhibitors of Sodium glucose transporter 2 (SGLT2i) (versus RAS blockade or SGLT2i alone) after two years of evolution in IgAN patients with severe histological lesions.

NCT ID: NCT01758120 Active, not recruiting - IgA Nephropathy Clinical Trials

Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

TOPplus-IgAN
Start date: December 2012
Phase: Phase 4
Study type: Interventional

Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.

NCT ID: NCT00378443 Active, not recruiting - Clinical trials for Glomerulonephritis, IGA

ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT

Start date: January 2006
Phase: N/A
Study type: Interventional

IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.